Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure
Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
This study is a 48-week study to evaluate the efficacy and safety of an investigational
regimen combining FDA approved HIV drugs in antiretroviral-experienced subjects failing on
their first highly active antiretroviral therapy regimen.
Phase:
Phase 4
Details
Lead Sponsor:
ViiV Healthcare
Treatments:
Abacavir Dideoxynucleosides Lamivudine Lamivudine, zidovudine drug combination Tenofovir Zidovudine